| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 114,249 | 101,200 | ||
| General and administrative | 17,513 | 26,024 | ||
| Total operating expenses | 131,762 | 127,224 | ||
| Interest income, net | 5,604 | 6,337 | ||
| Other income, net | 250 | 1,187 | ||
| Loss before provision for income taxes | -125,908 | -119,700 | ||
| Provision for income taxes | 594 | 913 | ||
| Net loss | -126,502 | -120,613 | ||
| Net loss per common share - basic (in dollars per share) | -0.73 | -0.71 | ||
| Net loss per common share - diluted (in dollars per share) | -0.73 | -0.71 | ||
| Weighted-average common shares outstanding basic (in shares) | 173,643,829 | 170,872,994 | ||
| Weighted-average common shares outstanding diluted (in shares) | 173,643,829 | 170,872,994 | ||
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)